Noelia Samartin-Veiga

Noelia Samartin-Veiga

Auto-generated profile, based on publicly available information

Noelia Samartin-Veiga

Brain and Pain (BaP) Lab, Departamento de Psicoloxía Clínica y Psicobioloxía, Facultade de Psicoloxia, Universidade de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in Pain
Verified
Journal Article
Closed access
NSNoelia Samartin-Veiga
Noelia Samartin-Veiga
MPMarina Pidal-Miranda
Marina Pidal-Miranda
AGAlberto J. González-Villar
Alberto J. González-Villar
CBClaire Bradley
Claire Bradley
LGLuis Garcia-Larrea
Luis Garcia-Larrea
MCMaría T. Carrillo-De-La-Peña
María T. Carrillo-De-La-Peña
Transcranial direct current stimulation (tDCS) over the primary motor cortex (M1) and the dorsolateral prefrontal cortex seem to improve pain and other symptoms of fibromyalgia (FM), although the evidence on the effectiveness of tDCS and the optimal stimulation target is not robust enough. Our main objective was to establish the optimal area of stimulation, comparing the 2 classical targets and a novel pain-related area, the operculo-insular cortex, in a sham-controlled trial. Using a double-blind design, we randomly assigned 130 women with FM to 4 treatment groups (M1, dorsolateral prefrontal cortex, operculo-insular cortex, and sham), each receiving fifteen 20-minute sessions of 2 mA anodal tDCS over the left hemisphere. Our primary outcome was pain intensity. The secondary outcomes were the other core symptoms of FM (fatigue, mood, cognitive and sleep disorders, and hyperalgesia measured by the pressure pain threshold). We performed the assessment at 3 time points (before, immediately after treatment, and at 6 months follow-up). The linear mixed-model analysis of variances showed significant treatment effects across time for clinical pain and for fatigue, cognitive and sleep disturbances, and experimental pain, irrespective of the group. In mood, the 3 active tDCS groups showed a significantly larger improvement in anxiety and depression than sham. Our findings provide evidence of a placebo effect, support the use of tDCS for the treatment of affective symptoms, and challenge the effectiveness of tDCS as treatment of FM.

1 January 2019 in NeuroImage: Clinical
Verified
Journal Article
Open access
NSN. Samartin-Veiga
N. Samartin-Veiga
AGAlberto González-Villar
Alberto González-Villar
MCM.T. Carrillo-De-La-Peña
M.T. Carrillo-De-La-Peña
Fibromyalgia (FM) is a generalized chronic pain syndrome of unknown aetiology. Although FM patients frequently complain of cognitive dysfunction, this is one of the least studied symptoms. Research on brain activity associated with the perceived cognitive impairment is particularly scarce. To address this gap, we recorded the brain electrical activity in participants during a cognitive control task. Electroencephalograms (EEGs) were recorded in 19 FM patients and 22 healthy controls (all women) while they performed the Multi-Source Interference Task (MSIT). We analyzed the amplitude of the frontal N2 and parietal P3 components elicited in control and interference trials and their relation with reaction times. We also explored the relationship of perceived cognitive dysfunction, assessed using visual analogue scales (VAS) and the Memory Failures of Everyday (MFE-30) test, with N2 and P3 amplitudes. The N2 amplitudes were smaller in FM patients than in controls and were negatively associated with cognitive complaints. Unlike patients, healthy controls showed significant differences in the amplitude of P3 obtained from control vs. interference trials of the MSIT. Smaller N2 and P3 amplitudes were associated to longer reaction times. The findings suggest a reduction in frontal brain activity during performance of an interference task, which was associated with the patients' cognitive complaints. Findings on P3 suggest altered modulation of attention according to the task demands in FM patients. Deficits in flexibility in the allocation of attentional resources and cognitive control during complex tasks may explain the dyscognition reported by chronic pain patients.

1 March 2022 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
NSN. Samartin-Veiga
N. Samartin-Veiga
AGAlberto González-Villar
Alberto González-Villar
MPM. Pidal-Miranda
M. Pidal-Miranda
AVA. Vázquez-Millán
A. Vázquez-Millán
MCM. T. Carrillo-De-La-Peña
M. T. Carrillo-De-La-Peña
Purpose: Fibromyalgia (FM) is a chronic pain syndrome with a strong impact on quality of life (QoL). Treatment of this condition remains a challenge, due to the scarce evidence for the effectiveness of the therapeutic approaches available. Current attention is focused on transcranial direct current stimulation (tDCS), which has yielded promising results for pain treatment. Rather than focusing only on pain relief, in this study, we aimed to determine how active or sham tDCS (over three cortical targets -the primary motor cortex, the dorsolateral prefrontal cortex and the operculo-insular cortex-) affect QoL in patients with FM. Methods: Using a double-blind, placebo-controlled design, we applied fifteen tDCS sessions of 20’ to initial 130 participants (randomized to any of the four treatment groups). We evaluated the QoL (assessed by SF-36) and the symptoms’ impact (assessed by FIQ-R) in baseline, after treatment and at 6 months follow-up. Results: All groups were comparable as regards age, medication pattern and severity of symptoms before the treatment. We found that QoL and symptoms’ impact improved in all treatment groups (including the sham) and this improvement lasted for up to 6 months. However, we did not observe any group effect nor group*treatment interaction. Conclusions: After the intervention, we observed a non-specific effect that may be due to placebo, favoured by the expectations of tDCS efficacy and psychosocial variables inherent to the intervention (daily relationship with therapists and other patients in the clinic). Therefore, active tDCS is not superior to sham stimulation in improving QoL in FM.

14 December 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NSN. Samartin-Veiga
N. Samartin-Veiga
AGA. J. González-Villar
A. J. González-Villar
YTY. Triñanes
Y. Triñanes
CGC. Gómez-Perretta
C. Gómez-Perretta
MCM. T. Carrillo-De-La-Peña
M. T. Carrillo-De-La-Peña
Fibromyalgia (FM) has been associated to an increased processing of somatosensory stimuli, but its generalization to other sensory modalities is under discussion. To clarify this, we studied auditory event-related potentials (AEPs) to stimuli of different intensity in patients with FM and healthy controls (HCs), considering the effects of attention mechanisms and medication. We performed two experiments: In study 1 (n = 50 FM, 60 HCs), the stimuli were presented randomly within the sequence; in study 2 (n = 28 FM, 30 HCs), they were presented in blocks of the same intensity. We analyzed intensity and group effects on N1-P2 amplitude and, only for the FM group, the effect of medication and the correlation between AEPs and clinical variables. Contrary to the expectation, the patients showed a trend of reduced AEPs to the loudest tones (study 1) or no significant differences with the HCs (study 2). Medication with central effects significantly reduced AEPs, while no significant relationships between the N1-P2 amplitude/intensity function and patients’ symptoms were observed. The findings do not provide evidence of augmented auditory processing in FM. Nevertheless, given the observed effect of medication, the role of sensory amplification as an underlying pathophysiological mechanism in fibromyalgia cannot be discarded.

24 July 2023 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
NSN. Samartin-Veiga
N. Samartin-Veiga
AGAlberto González-Villar
Alberto González-Villar
MPM. Pidal-Miranda
M. Pidal-Miranda
AVA. Vázquez-Millán
A. Vázquez-Millán
MCM. T. Carrillo-De-La-Peña
M. T. Carrillo-De-La-Peña

18 May 2026 in Pain Management Nursing
Verified
Journal Article
Open access
AGAntonio Gil-Ugidos
Antonio Gil-Ugidos
JEJorge Miguel Alcántara Espinosa
Jorge Miguel Alcántara Espinosa
LRLara Rubal-Otero
Lara Rubal-Otero
MMMónica Mayo-Moldes
Mónica Mayo-Moldes
NSNoelia Samartin-Veiga
Noelia Samartin-Veiga
MCMaría Teresa Carrillo-De-La-Peña
María Teresa Carrillo-De-La-Peña
Pharmacological interventions for chronic pain (CP) show limited evidence and adverse side effects, and thus, the management of CP represents a challenge for the healthcare systems. In the last few years, transcranial Electrical Stimulation (tES) has yielded positive results in relieving pain in patients with CP. However, the evidence has been obtained through group-level analyses without considering patient profiles that may benefit most from this technique. In this secondary analysis, we utilized data from a clinical trial involving 96 CP patients who undertook 15 daily consecutive sessions of tES at home of either transcranial Direct Current Stimulation or transcranial Alternate Current Stimulation. With the aim of ascertaining the predictors of treatment efficacy, we carried out a comparison between responders (patients with a pain intensity reduction of 30% or more after the tES treatment) and non-responders and built a multivariable binary logistic regression model. Only 24% of the patients reported a clinically significant improvement in pain intensity. Comparison between the clinical characteristics of patients showed that depression and anxiety-related variables appear to be the most closely related to treatment response. Moreover, finding signs that the number of years with depression and the onset of depression could be the variables with the highest (nearly significant) association with treatment response. These results provide preliminary clues to profile patients who could benefit more from tES, an important step to personalize neuromodulation treatments. Identifying CP patients who could benefit most from tES treatments could help clinicians with decision-making and reduce patient suffering through personalized treatments.